Acacia names new board members
This article was originally published in Scrip
Acacia Pharma, a company specializing in the development of drugs for supportive care, has named Scott Byrd and Christine Soden to its board of directors. Mr Byrd was most recently the chief commercial officer of Cadence Pharmaceuticals until the company's acquisition by Mallinckrodt Pharmaceuticals in March 2014. Previously, Mr Byed held a variety of US and global roles in sales, marketing, finance, manufacturing and strategic planning at Lilly.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.